<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01029704</url>
  </required_header>
  <id_info>
    <org_study_id>THR-1442-C-402</org_study_id>
    <nct_id>NCT01029704</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase II, Four-week, Multi-center, Double-blind, Placebo-controlled Parallel Group Study to Evaluate the Safety and Efficacy of EGT0001442 in Type 2 Diabetic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theracos</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theracos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of EGT0001442 on fasting plasma glucose
      after 28 days of treatment in subjects with type 2 diabetes.

      The study will also assess the pharmacokinetics (how much of the drug gets into the blood and
      how long it takes the body to get rid of it), safety and tolerability of EGT0001442, the
      effect on weight and HbA1c as well as the effect EGT0001442 has on the amount of glucose
      produced in the body by the urine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes From the Baseline in the Fasting Plasma Glucose at End of 28 Days</measure>
    <time_frame>baseline (day 1) and 28 days</time_frame>
    <description>Fasting glucose levels were measured at two time points; on day 1 (baseline) and day 28 (end of treatment). Changes in the fasting plasma glucose level during the study period was calculated by reducing the baseline glucose level (day 1) from glucose level at end of treatment (day 28) (i.e glucose level on day 28 minus glucose level on Day 1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From the Baseline in the Body Weight at End of 28 Days</measure>
    <time_frame>baseline (day 1) and 28 days</time_frame>
    <description>Body weight was measured at two time points; on day 1 (baseline) and day 28 (end of treatment). Changes in the body weight during the study period was calculated by reducing the baseline body weight (day 1) from body weight at end of treatment (day 28) (i.e body weight on day 28 minus body weight on Day 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From the Baseline in the Hemoglobin A1c (HbA1c) at End of 28 Days</measure>
    <time_frame>baseline (day 1) and 28 days</time_frame>
    <description>HbA1c levels were measured at two time points; on day 1 (baseline) and day 28 (end of treatment). Changes in the HbA1c level during the study period was calculated by reducing the baseline HbA1c level (day 1) from HbA1c level at end of treatment (day 28) (i.e HbA1c level on day 28 minus HbA1c level on Day 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From the Baseline in the Urinary Glucose Excretion at End of 28 Days</measure>
    <time_frame>baseline (day 1) and 28 days</time_frame>
    <description>Urinary glucose levels were measured at two time points; on day 1 (baseline) and day 28 (end of treatment). Changes in the urinary glucose level during the study period was calculated by reducing the baseline urinary glucose level (day 1) from urinary glucose level at end of treatment (day 28) (i.e urinary glucose level on day 28 minus urinary glucose level on Day 1).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>EGT0001442</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGT0001442</intervention_name>
    <description>Segment 1 is a single center, open labeled, ascending dose study in diabetic subjects who will receive 5, 10, 20, or 50 mg of EGT0001442 capsules orally once daily for 28 days.
Segment 2 is a multi-center, double-blind, placebo-controlled parallel group study. Diabetic subjects will be randomly assigned to receive oral EGT0001442 at 5, 10, 20, or 50 mg/day for 28 days.</description>
    <arm_group_label>EGT0001442</arm_group_label>
    <other_name>Human SGLT2 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsules to match EGT0001442</intervention_name>
    <description>Segment 1: Not applicable.
Segment 2: Diabetic subjects will be randomly assigned to receive oral placebo once daily for 28 days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Human SGLT2 inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between the ages of 18 and 70 years diagnosed with type 2 diabetes.

          -  Body mass index (BMI) between 18 kg/m2 and 37 kg/m2 (inclusive).

          -  HbA1c levels between 6.5 and 9.5 (inclusive) where the upper limit of normal for the
             HbA1c assay is 6.4% or HbA1c levels between 6.2 and 9.5% (inclusive) where the upper
             limit of normal for the HbA1c assay is 6.1%.

          -  Fasting plasma glucose levels between 126 and 270 mg/dL (7 - 15 mmol/L, inclusive)
             while on diabetic medications.

          -  Treatment na√Øve subjects with HbA1c between 6.5 and 9.5 and fasting plasma glucose
             between 126 and 270 mg/dL (7 - 15 mmol/L).

          -  If taking drugs for diabetes, must be medically able and willing to discontinue
             diabetic medications for the duration of the study.

          -  Female subjects must be surgically sterilized or postmenopausal.

        Exclusion Criteria:

          -  Type 1 diabetes or diabetes treated with insulin injection.

          -  Insulin therapy or oral antidiabetic medication other than metformin, sitagliptin,
             saxagliptin, a sulfonylurea or combination of these.

          -  Sitting blood pressure above 150/95 mmHg on two evaluations at least 10 minutes apart
             at screening.

          -  Positive results on screen for drugs of abuse.

          -  Previous treatment with an investigational drug within 30 days or 7 half-lives,
             whichever is longer.

          -  Previous treatment with EGT0001474 or EGT0001442.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mason W Freeman, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site #10</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #04</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #12</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #07</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #08</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #06</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #11</name>
      <address>
        <city>Desoto</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #01</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #15</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #03</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #13</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site #02</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2009</study_first_submitted>
  <study_first_submitted_qc>December 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2009</study_first_posted>
  <results_first_submitted>June 21, 2011</results_first_submitted>
  <results_first_submitted_qc>June 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 20, 2011</results_first_posted>
  <last_update_submitted>July 27, 2013</last_update_submitted>
  <last_update_submitted_qc>July 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus Type 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Received no drug (EGT0001442) during 28 days</description>
        </group>
        <group group_id="P2">
          <title>EGT0001442 5mg</title>
          <description>Received 5mg of EGT0001442 per day for 28 days</description>
        </group>
        <group group_id="P3">
          <title>EGT0001442 10mg</title>
          <description>Received 10mg of EGT0001442 per day for 28 days</description>
        </group>
        <group group_id="P4">
          <title>EGT0001442 20mg</title>
          <description>Received 20mg of EGT0001442 per day for 28 days</description>
        </group>
        <group group_id="P5">
          <title>EGT0001442 50mg</title>
          <description>Received 50mg of EGT0001442 per day for 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Received no drug (EGT0001442) during 28 days</description>
        </group>
        <group group_id="B2">
          <title>EGT0001442 5mg</title>
          <description>Received 5mg of EGT0001442 per day for 28 days</description>
        </group>
        <group group_id="B3">
          <title>EGT0001442 10mg</title>
          <description>Received 10mg of EGT0001442 per day for 28 days</description>
        </group>
        <group group_id="B4">
          <title>EGT0001442 20mg</title>
          <description>Received 20mg of EGT0001442 per day for 28 days</description>
        </group>
        <group group_id="B5">
          <title>EGT0001442 50mg</title>
          <description>Received 50mg of EGT0001442 per day for 28 days</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="28"/>
            <count group_id="B5" value="26"/>
            <count group_id="B6" value="129"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.7" spread="7.3"/>
                    <measurement group_id="B2" value="57.8" spread="6.9"/>
                    <measurement group_id="B3" value="54.9" spread="9"/>
                    <measurement group_id="B4" value="59" spread="7.1"/>
                    <measurement group_id="B5" value="54.7" spread="6.7"/>
                    <measurement group_id="B6" value="57.1" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes From the Baseline in the Fasting Plasma Glucose at End of 28 Days</title>
        <description>Fasting glucose levels were measured at two time points; on day 1 (baseline) and day 28 (end of treatment). Changes in the fasting plasma glucose level during the study period was calculated by reducing the baseline glucose level (day 1) from glucose level at end of treatment (day 28) (i.e glucose level on day 28 minus glucose level on Day 1).</description>
        <time_frame>baseline (day 1) and 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Received no drug (EGT0001442) during 28 days</description>
          </group>
          <group group_id="O2">
            <title>EGT0001442 5mg</title>
            <description>Received 5mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O3">
            <title>EGT0001442 10mg</title>
            <description>Received 10mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O4">
            <title>EGT0001442 20mg</title>
            <description>Received 20mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O5">
            <title>EGT0001442 50mg</title>
            <description>Received 50mg of EGT0001442 per day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From the Baseline in the Fasting Plasma Glucose at End of 28 Days</title>
          <description>Fasting glucose levels were measured at two time points; on day 1 (baseline) and day 28 (end of treatment). Changes in the fasting plasma glucose level during the study period was calculated by reducing the baseline glucose level (day 1) from glucose level at end of treatment (day 28) (i.e glucose level on day 28 minus glucose level on Day 1).</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.63" spread="33.51"/>
                    <measurement group_id="O2" value="-24.25" spread="41.03"/>
                    <measurement group_id="O3" value="-29" spread="38.3"/>
                    <measurement group_id="O4" value="-36.14" spread="47.13"/>
                    <measurement group_id="O5" value="-41.64" spread="41.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From the Baseline in the Body Weight at End of 28 Days</title>
        <description>Body weight was measured at two time points; on day 1 (baseline) and day 28 (end of treatment). Changes in the body weight during the study period was calculated by reducing the baseline body weight (day 1) from body weight at end of treatment (day 28) (i.e body weight on day 28 minus body weight on Day 1).</description>
        <time_frame>baseline (day 1) and 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Received no drug (EGT0001442) during 28 days</description>
          </group>
          <group group_id="O2">
            <title>EGT0001442 5mg</title>
            <description>Received 5mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O3">
            <title>EGT0001442 10mg</title>
            <description>Received 10mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O4">
            <title>EGT0001442 20mg</title>
            <description>Received 20mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O5">
            <title>EGT0001442 50mg</title>
            <description>Received 50mg of EGT0001442 per day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From the Baseline in the Body Weight at End of 28 Days</title>
          <description>Body weight was measured at two time points; on day 1 (baseline) and day 28 (end of treatment). Changes in the body weight during the study period was calculated by reducing the baseline body weight (day 1) from body weight at end of treatment (day 28) (i.e body weight on day 28 minus body weight on Day 1).</description>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="1.5"/>
                    <measurement group_id="O2" value="-0.76" spread="1.8"/>
                    <measurement group_id="O3" value="-0.64" spread="1.26"/>
                    <measurement group_id="O4" value="-1.64" spread="1.22"/>
                    <measurement group_id="O5" value="-1.74" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From the Baseline in the Hemoglobin A1c (HbA1c) at End of 28 Days</title>
        <description>HbA1c levels were measured at two time points; on day 1 (baseline) and day 28 (end of treatment). Changes in the HbA1c level during the study period was calculated by reducing the baseline HbA1c level (day 1) from HbA1c level at end of treatment (day 28) (i.e HbA1c level on day 28 minus HbA1c level on Day 1).</description>
        <time_frame>baseline (day 1) and 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Received no drug (EGT0001442) during 28 days</description>
          </group>
          <group group_id="O2">
            <title>EGT0001442 5mg</title>
            <description>Received 5mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O3">
            <title>EGT0001442 10mg</title>
            <description>Received 10mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O4">
            <title>EGT0001442 20mg</title>
            <description>Received 20mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O5">
            <title>EGT0001442 50mg</title>
            <description>Received 50mg of EGT0001442 per day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From the Baseline in the Hemoglobin A1c (HbA1c) at End of 28 Days</title>
          <description>HbA1c levels were measured at two time points; on day 1 (baseline) and day 28 (end of treatment). Changes in the HbA1c level during the study period was calculated by reducing the baseline HbA1c level (day 1) from HbA1c level at end of treatment (day 28) (i.e HbA1c level on day 28 minus HbA1c level on Day 1).</description>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.59"/>
                    <measurement group_id="O2" value="-0.21" spread="0.49"/>
                    <measurement group_id="O3" value="0.02" spread="0.41"/>
                    <measurement group_id="O4" value="0.19" spread="0.52"/>
                    <measurement group_id="O5" value="-0.2" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From the Baseline in the Urinary Glucose Excretion at End of 28 Days</title>
        <description>Urinary glucose levels were measured at two time points; on day 1 (baseline) and day 28 (end of treatment). Changes in the urinary glucose level during the study period was calculated by reducing the baseline urinary glucose level (day 1) from urinary glucose level at end of treatment (day 28) (i.e urinary glucose level on day 28 minus urinary glucose level on Day 1).</description>
        <time_frame>baseline (day 1) and 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Received no drug (EGT0001442) during 28 days</description>
          </group>
          <group group_id="O2">
            <title>EGT0001442 5mg</title>
            <description>Received 5mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O3">
            <title>EGT0001442 10mg</title>
            <description>Received 10mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O4">
            <title>EGT0001442 20mg</title>
            <description>Received 20mg of EGT0001442 per day for 28 days</description>
          </group>
          <group group_id="O5">
            <title>EGT0001442 50mg</title>
            <description>Received 50mg of EGT0001442 per day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From the Baseline in the Urinary Glucose Excretion at End of 28 Days</title>
          <description>Urinary glucose levels were measured at two time points; on day 1 (baseline) and day 28 (end of treatment). Changes in the urinary glucose level during the study period was calculated by reducing the baseline urinary glucose level (day 1) from urinary glucose level at end of treatment (day 28) (i.e urinary glucose level on day 28 minus urinary glucose level on Day 1).</description>
          <units>g/24h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="14.98"/>
                    <measurement group_id="O2" value="22.57" spread="16.56"/>
                    <measurement group_id="O3" value="18.71" spread="20.46"/>
                    <measurement group_id="O4" value="21.01" spread="16.43"/>
                    <measurement group_id="O5" value="26.8" spread="19.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Received no drug (EGT0001442) during 28 days</description>
        </group>
        <group group_id="E2">
          <title>EGT0001442 5mg</title>
          <description>Received 5mg of EGT0001442 per day for 28 days</description>
        </group>
        <group group_id="E3">
          <title>EGT0001442 10mg</title>
          <description>Received 10mg of EGT0001442 per day for 28 days</description>
        </group>
        <group group_id="E4">
          <title>EGT0001442 20mg</title>
          <description>Received 20mg of EGT0001442 per day for 28 days</description>
        </group>
        <group group_id="E5">
          <title>EGT0001442 50mg</title>
          <description>Received 50mg of EGT0001442 per day for 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yuan-Di C. Halvorsen, PhD</name_or_title>
      <organization>Theracos, Inc.</organization>
      <phone>617-726-4236</phone>
      <email>yhalvorsen@ccib.mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

